Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NSPH Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
Nanosphere: Despite The Depressed Outlook There Are Still Aspects To Remain Bullish, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/nanosphere-despite-the-depressed-outlook-there-are-still-aspects-to-remain-bullish-says-roth-capital/
$NPSP NPS Pharmaceuticals Shares Remain Undervalued, Says Janney Capital
http://www.smarteranalyst.com/2014/08/08/nps-pharmaceuticals-shares-remain-undervalued-says-janney-capital/
Cantor Fitzgerald Reiterates Hold On Jazz Pharmaceuticals Following 2Q14 Results http://www.smarteranalyst.com/2014/08/08/cantor-fitzgerald-reiterates-hold-on-jazz-pharmaceuticals-following-2q14-results/
$GMCR Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
$GMCR Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
$GMCR Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
$GMCR Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
$GMCR Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
Roth Capital Sees Little Near-Term Price Upside For Keurig Shares http://www.smarteranalyst.com/2014/08/08/roth-capital-sees-little-near-term-price-upside-for-keurig-shares/
$ETRM Roth Capital Maintains Buy On EnteroMedics Following 2Q14 Results http://www.smarteranalyst.com/2014/08/08/roth-capital-maintains-buy-on-enteromedics-following-2q14-results/
Another recommendation by Roth Capital.
$DEPO Depomed: We Remain Neutral On The Name But With A Positive Bias, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/depomed-we-remain-neutral-on-the-name-but-with-a-positive-bias-says-roth-capital/
Depomed: We Remain Neutral On The Name But With A Positive Bias, Says Roth Capital http://www.smarteranalyst.com/2014/08/08/depomed-we-remain-neutral-on-the-name-but-with-a-positive-bias-says-roth-capital/
$CLDX Roth Capital Reiterates Buy On Celldex Following 2Q14 Results, Keeps $40 PT http://www.smarteranalyst.com/2014/08/08/roth-capital-reiterates-buy-on-celldex-following-2q14-results-keeps-40-pt/
Roth Capital Reiterates Buy On Celldex Following 2Q14 Results, Keeps $40 PT http://bit.ly/1kO5qfd
Atmel: We Recommend Investors Remain On The Sidelines, Says Feltl http://www.smarteranalyst.com/2014/08/08/atmel-we-recommend-investors-remain-on-the-sidelines-says-feltl/
$ACAD ACADIA Pharmaceuticals Quarterly Update; Cowen Reiterates Buy http://www.smarteranalyst.com/2014/08/07/acadia-pharmaceuticals-quarterly-update-cowen-reiterates-buy/
ACADIA Pharmaceuticals Quarterly Update; Cowen Reiterates Buy http://www.smarteranalyst.com/2014/08/07/acadia-pharmaceuticals-quarterly-update-cowen-reiterates-buy/
$GWPH We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen http://www.smarteranalyst.com/2014/08/07/we-expect-gws-shares-to-outperform-as-its-pipeline-progresses-says-cowen/
We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen http://www.smarteranalyst.com/2014/08/07/we-expect-gws-shares-to-outperform-as-its-pipeline-progresses-says-cowen/
Cowen Maintains Market Perform On XenoPort Following 2Q14 Results http://www.smarteranalyst.com/2014/08/07/cowen-maintains-market-perform-on-xenoport-following-2q14-results/
Avanir Offers Investors A Unique Investment Opportunity, Says Cowen http://www.smarteranalyst.com/2014/08/07/avanir-offers-investors-a-unique-investment-opportunity-says-cowen/
$ARIA We Think ARIA Is Fairly Valued, Says Cowen; Reaffirms Market Perform Following 2Q14 Results http://www.smarteranalyst.com/2014/08/07/we-think-aria-is-fairly-valued-says-cowen-reaffirms-market-perform-following-2q14-results/
We Think ARIA Is Fairly Valued, Says Cowen; Reaffirms Market Perform Following 2Q14 Results http://www.smarteranalyst.com/2014/08/07/we-think-aria-is-fairly-valued-says-cowen-reaffirms-market-perform-following-2q14-results/
BioCryst Pharmaceuticals Quarterly Update; Roth Capital Reiterates Buy http://www.smarteranalyst.com/2014/08/07/biocryst-pharmaceuticals-quarterly-update-roth-capital-reiterates-buy/
H.C. Wainwright Reiterates Buy On BioCryst Pharmaceuticals, Sees 84% Upside http://www.smarteranalyst.com/2014/08/07/h-c-wainwright-reiterates-buy-on-biocryst-pharmaceuticals-sees-84-upside/
$ZAGG Roth Capital Reiterates Neutral Stance On Zagg Following Q214 Results As Concerns Still Surrounding http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-neutral-stance-on-zagg-following-q214-results-as-concerns-still-surrounding/
Roth Capital Reiterates Neutral Stance On Zagg Following Q214 Results As Concerns Still Surrounding http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-neutral-stance-on-zagg-following-q214-results-as-concerns-still-surrounding/
$SNTA Roth Capital Reiterates Buy On Synta Following 2Q14 Results And New CEO Announcement http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-buy-on-synta-following-2q14-results-and-new-ceo-announcement/
$SNTA Roth Capital Reiterates Buy On Synta Following 2Q14 Results And New CEO Announcement http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-buy-on-synta-following-2q14-results-and-new-ceo-announcement/
$SCMP Cantor Fitzgerald Reiterates Buy On Sucampo Following 2Q14 Results; Keeps $12 PT http://www.smarteranalyst.com/2014/08/07/cantor-fitzgerald-reiterates-buy-on-sucampo-following-2q14-results-keeps-12-pt/
Cantor Fitzgerald Reiterates Buy On Sucampo Following 2Q14 Results; Keeps $12 PT http://www.smarteranalyst.com/2014/08/07/cantor-fitzgerald-reiterates-buy-on-sucampo-following-2q14-results-keeps-12-pt/
$RGSE Roth Capital Reiterates Buy On Real Goods Solar Into 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-buy-on-real-goods-solar-into-2q14-earnings-results/
$RGSE Roth Capital Reiterates Buy On Real Goods Solar Into 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-buy-on-real-goods-solar-into-2q14-earnings-results/
Roth Capital Reiterates Buy On Real Goods Solar Into 2Q14 Earnings Results http://www.smarteranalyst.com/2014/08/07/roth-capital-reiterates-buy-on-real-goods-solar-into-2q14-earnings-results/